Veracyte Board Member Eastham Strengthens Position with New Stock Grant

Rhea-AI Filing Summary

Veracyte Director Karin Eastham received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025, as reported in this Form 4 filing. The RSUs were awarded at $0 cost and will vest in full on either:

• The first anniversary of the grant date (June 18, 2026), or
• Immediately prior to Veracyte's next annual stockholder meeting, whichever comes first
• Additionally, full vesting occurs upon any change in control of the company

Following this transaction, Eastham now beneficially owns 23,228 shares of Veracyte common stock directly. This equity grant appears to be part of the company's director compensation program. The filing was signed by Jonathan Wygant as attorney-in-fact on June 23, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider EASTHAM KARIN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9,321	$0.00	--

Holdings After Transaction: Common Stock — 23,228 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EASTHAM KARIN

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A(1)		9,321	A	$0	23,228	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many VCYT shares did Director Karin Eastham receive on June 18, 2025?

According to the Form 4 filing, Director Karin Eastham received 9,321 shares of VCYT common stock as restricted stock units (RSUs) on June 18, 2025.

What is the vesting schedule for VCYT Director Eastham's June 2025 RSU grant?

The restricted stock units vest in full on either: 1) the first anniversary of the grant date (June 18, 2026), or 2) immediately prior to VCYT's next annual meeting of stockholders, whichever comes earlier. Additionally, the RSUs will vest completely if there is a change in control of the company.

How many VCYT shares does Karin Eastham own after the June 2025 RSU grant?

Following the RSU grant transaction, Karin Eastham directly owns 23,228 shares of Veracyte (VCYT) common stock.

What was the purchase price of VCYT shares granted to Director Eastham?

The restricted stock units were granted to Director Eastham at $0 cost, as they represent equity compensation for her role as a director of Veracyte (VCYT).